AbbVie's Atogepant And OnabotulinumtoxinA Receive Strong Recommendations In The Newly Updated Canadian Headache Society Migraine Prevention Guideline; A Strong Recommendation Was Issued When An Intervention Was Deemed Suitable For The Majority Of Patients, With Benefits Outweighing Potential Risks

• The 2024 Canadian Headache Society (CHS) Migraine Prevention Guideline, which replaces the previous version published in 2012, granted strong recommendations for atogepant in episodic and chronic migraine, and for onabotulinumtoxinA in chronic migraine.1
• The new CHS Migraine Prevention Guideline is based on a comprehensive systematic review and meta-analysis and addresses both episodic and chronic migraine.1
• A strong recommendation was issued when an intervention was deemed suitable for the majority of patients, with benefits outweighing potential risks.1

MONTRÉAL, Dec. 19, 2024 /CNW/ - AbbVie (NYSE:ABBV) announced today that atogepant and onabotulinumtoxinA have received strong recommendations in the newly updated CHS Migraine Prevention Guideline: atogepant is strongly recommended in the treatment of episodic and chronic migraine, and onabotulinumtoxinA, in the treatment of chronic migraine (please refer to the guideline for the full recommendations). The 2024 version marks a crucial step forward in equipping healthcare professionals with the most current, evidence-based recommendations for preventing and managing migraines – a condition that impacts millions of Canadians.2